Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13621945 | 0.78 | — | — | |
| SCHEMBL12907101 | 0.78 | PGR (0.32) | — | |
| SCHEMBL30104097 | 0.71 | PGR (0.44) | CYP2A6 | |
| SCHEMBL22342729 | 0.70 | — | — | |
| SCHEMBL27779510 | 0.69 | — | — | |
| SCHEMBL346857 | 0.67 | — | — | |
| SCHEMBL23006 | 0.67 | — | — | |
| SCHEMBL1363558 | 0.65 | — | — | |
| SCHEMBL8222639 | 0.65 | — | — | |
| SCHEMBL1244973 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12102715-B1 | ROS-responsive liposomes for specific targeting | VERILY LIFE SCIENCES LLC (US) | 2024-10-01 | — | — | US | claimed |
| CN-116813602-A | Multiple stimulus response type photochemical sensor and preparation method and application thereof | 豫章师范学院 | 2023-09-29 | — | — | CN | claimed |
| US-11179335-B1 | ROS-responsive liposomes for specific targeting | VERILY LIFE SCIENCES LLC (US) | 2021-11-23 | — | — | US | claimed |
| US-10517823-B1 | ROS—responsive liposomes for specific targeting | VERILY LIFE SCIENCES LLC (US) | 2019-12-31 | — | — | US | claimed |
| CN-116813602-B | Multiple stimulus response type photochemical sensor and preparation method and application thereof | 豫章师范学院 | 2025-08-26 | — | — | CN | disclosed |
| EP-4558511-A2 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | Firefly Bio, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024263969-A2 | HETEROARYL COMPOUNDS AS ENDOCANNABINOID SYSTEM MODULATORS AND USES THEREOF | NORTHEASTERN UNIVERSITY (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| US-12102715-B1 | ROS-responsive liposomes for specific targeting | VERILY LIFE SCIENCES LLC (US) | 2024-10-01 | — | — | US | disclosed |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-25 | — | — | US | disclosed |
| EP-1453847-A1 | 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-6689772-B1 | ANTINEOPLASTIC AGENTS; OSTEOPOROSIS; POLYCYSTIC KIDNEY DISEASE; ANTIVIRAL AGENTS | WYETH | 2004-02-10 | — | — | US | disclosed |
| US-20030220272-A1 | 6-O-acyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003050132-A1 | 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| US-6521618-B2 | Antineoplastic agents, agents for treatment of osteoporosis and polycystic kidney disease | WYETH | 2003-02-18 | — | — | US | disclosed |
| EP-1268431-A1 | 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS | Wyeth (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020026052-A1 | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-02-28 | — | — | US | disclosed |
| WO-2001072711-A1 | 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220272-A1 | 6-O-acyl ketolide antibacterials | Q6ZSR9, ACSL6, RPS4Y1 | KDM4E 18/4885CYP2A6 194/4885 |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | KDM4E 2418/4885CYP2A6 4398/4885 |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | KDM4E 4391/4885CYP2A6 1913/4885 |
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | MGMT, MCL1, FANCF | KDM4E 1910/4885CYP2A6 200/4885 |
| US-20020026052-A1 | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | PKD1, PKD2, CSNK1A1 | KDM4E 1875/4885CYP2A6 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.